18 Jul 2018 14:12
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 June 2018
Net Assets | £242m |
Net Assets per share | 646p |
Share price | 610p |
Total value of unquoted investments | £26m |
Total number of portfolio companies | 75 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Neurocrine | 5.0 |
Celgene | 4.7 |
Vertex | 4.4 |
Morphosys | 4.3 |
Illumina | 3.9 |
Array | 3.6 |
Genmab | 3.6 |
Regeneron | 3.4 |
Biogen | 3.3 |
Alexion | 3.2 |
----------- | |
Total | 39.4 |
Geographical Allocation | % NAV |
US & Canada | 85 |
Europe | 15 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 89 |
Unquoted | 11 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 34 |
Mid Cap =USD1-10BN | 42 |
Small Cap | 24 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 44 |
CNS | 14 |
Rare diseases | 13 |
Ophthalmology | 6 |
Inflammation | 5 |
Infectious Diseases | 3 |
Metabolic | 2 |
Medtech | 2 |
Other | 11 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
18 JULY 2018